Search

Displaying results 1431 - 1440 of 9667 in total
  1. Drug

    Neon

    go.drugbank.com/drugs/DB11589
    Approved

    It is a noble gas that is colorless, odorless, inert and monatomic. It is the fifth most abundant chemical element in the universe by mass but a rare element on Earth. … Neon may be used in the clinical setting as a diagnostic tracer gas in a gas analyzer for a lung diffusion test.

  2. Drug

    Dimethicone 410

    go.drugbank.com/drugs/DB14005
    Approved

    [L2162] The name dimethicone has a lot of nomenclature inconsistencies as it is used to refer to common names, generic names, trade names or even for the listing of mixtures. … [L1769] It is currently recognized by the FDA as a skin protectant OTC ingredient for human use in a concentration of 1-30%.

    Products: Gas Relief Ultra Strength
  3. Drug

    Gallium Ga-68 gozetotide

    go.drugbank.com/drugs/DB16019
    ApprovedInvestigational

    [L27006] On December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) … [L27006] It is administered intravenously.

  4. Drug

    Polysilicone-15

    go.drugbank.com/drugs/DB11271
    Approved

    It is the first polymeric UVB filer consisting of chromophores attached to a silicone backbone [L2796, L2797, L2799, F87, F88, F89]. … When included in various other cosmetic shampoos, conditioners, or hairsprays the compound also functions as an effective photostabilizer of the product [L2796, L2797, L2799, F87, F88, F89].

    Mixtures: OHUI SUN SCIENCE Perfect Sunblock Blue EX plus
  5. Drug

    Fluoroestradiol F-18

    go.drugbank.com/drugs/DB15690
    ApprovedInvestigational

    [A203912] Fluoroestradiol F-18 was first granted FDA approval in May 2020, and will be developed by PETNET Solutions, Inc. and Zionexa USA under the brand name Cerianna. … [L14096] The ability to image ER-positive tumors _in vivo_ is advantageous in that, while helping to visualize tumor progression/regression, it may also be used to assess for heterogeneity in ER expression

  6. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    The FDA approved imlunestrant on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with … [A256828] In clinical trials, imlunestrant has been investigated as monotherapy and in combination with other drugs in breast cancer patients.[A256828]

  7. Drug

    Intermedine

    go.drugbank.com/drugs/DB17612
    Investigational

    Synonyms: Active principle of the pars intermedia of the pituitary, Ac-ser-tyr-ser-met-glu-his-phe-arg-trp-gly-lys-pro-val-nh2
  8. Drug

    Chlormerodrin

    go.drugbank.com/drugs/DB00534
    ApprovedWithdrawn

    It is no longer used and has been replaced with new classes of diuretic drugs. … Chlormerodrin is a mercurial compound with toxic side effects that was previously used as a diuretic. The radiolabeled form has been used as a diagnostic and research tool.

  9. Drug

    Formestane

    go.drugbank.com/drugs/DB08905
    ApprovedWithdrawn

    Some clinical data has suggested that the clinically recommended dose of 250mg was too low. … It is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes.

  10. Drug

    Fosnetupitant

    go.drugbank.com/drugs/DB14019
    ApprovedInvestigational

    as major side effects. … Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg